drugset
drugset / Trial / NCT01377233

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCT01377233 ↗

Phase 2 Completed 46 enrolled H. Lundbeck A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.

Timeline

Start
2011-07
Primary completion
2012-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Zicronapine Small molecule 10 mg —
Subject Zicronapine Small molecule 20 mg —
Subject Zicronapine Small molecule 30 mg —
Subject Zicronapine Small molecule 45 mg —

Indications

schizophrenia